Levothyroxine NDAs May Be Refused Filing After First Product Approval - FDA

Levothyroxine NDAs may be refused filing following approval of the first levothyroxine product, FDA said in a draft guidance issued August 18.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet